Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)

NCT01547312 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: Peg-Interferon
PROCEDURE: Liver Samples from FNA
PROCEDURE: Liver Samples from CNB
PROCEDURE: Blood Samples
DRUG: Ribavirin
DRUG: 800 mg Grazoprevir
DRUG: 100 mg Grazoprevir
PROCEDURE: Liver samples from CNB and FNA

Sponsor

Merck Sharp & Dohme LLC